Bergamot
Best-in-class: Citrus Bergamot
A citrus polyphenol extract with strong evidence for improving cholesterol and metabolic markers — a natural lipid-support option.
Bergamot quick facts
| Suggested dose | 500–1,000 mg standardized extract daily. |
| How often | Daily |
| Who it's for | Cholesterol, triglyceride and metabolic support. |
The most credible natural lipid intervention in the Vault, with randomized trials showing meaningful LDL and triglyceride reduction. Effect sizes are well below a statin — this is not a substitute where the risk is high, and pretending otherwise costs people years of exposure. It is a legitimate option in statin intolerance or as an adjunct allowing a lower statin dose, which is a conversation to have with whoever prescribes it.
How Bergamot actually works
Citrus bergamot polyphenols — brutieridin and melitidin — are structurally similar to statins and appear to weakly inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis. Separately they activate AMPK, which suppresses hepatic lipogenesis, and improve glucose handling. That dual action is why bergamot moves triglycerides and glucose alongside LDL rather than LDL alone.
Where to get Bergamot
Find Bergamot on iHerb →The evidence for Bergamot
Graded by what exists behind each claim.
✅ Clinically validated
- Meta-analyses show reduced total and LDL cholesterol and triglycerides, with raised HDL.
- Also improves some glucose/insulin markers.
📊 Correlative data
- Its polyphenols act on the same lipid pathways as statins (HMG-CoA), more gently.
🧪 Theoretical / extrapolated benefits
- A statin-adjacent mechanism without statin side effects — promising, growing evidence.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Bergamot actually does
Bergamot is the one supplement in this category with a real pharmacophore rather than a vibe, and the pharmacophore has a name. Citrus bergamia juice carries the ordinary citrus flavanone glycosides — neoeriocitrin, naringin, neohesperidin — and then two molecules almost nothing else in the plant kingdom has: brutieridin and melitidin. Each is a flavanone glycoside carrying a 3-hydroxy-3-methylglutaryl group. That HMG moiety is the same fragment that sits at the business end of every statin, because it is the structural mimic of HMG-CoA, the substrate of HMG-CoA reductase. This is not a metaphor about “acting on the same pathway”; it is the same chemical group on a different scaffold.
What the cell work actually shows, and it is two mechanisms not one. In HepG2 hepatocytes and Caco-2 intestinal cells, bergamot extract lowers total and free cellular cholesterol and reduces HMGCR expression — note expression, meaning the amount of reductase protein transcribed, which is a different lever from a statin's direct active-site inhibition. Separately, brutieridin reduces cholesterol uptake in the Caco-2 monolayer Huang 2021. Caco-2 uptake is the enterocyte-absorption compartment, which is NPC1L1 territory — the ezetimibe target. So bergamot has a synthesis-side argument and an absorption-side argument, and they predict different things about who responds.
The vascular arm is a receptor, and it is named. In hyperlipidemic patients, adding bergamot to rosuvastatin reduced malondialdehyde and reduced expression of LOX-1 — the lectin-like oxidized-LDL receptor, gene OLR1, the endothelial scavenger receptor that takes up oxidized LDL and drives the endothelial dysfunction step of plaque initiation — alongside changed phosphorylation of protein kinase B Gliozzi 2013. That is a mechanistically distinct claim from lowering LDL: it says the particles that remain are being handled differently at the vessel wall.
And there is a second chemistry in this plant that has nothing to do with any of it. The peel oil of bergamot is the source of bergamottin, a furanocoumarin that inactivates cytochrome P450 3A4 by mechanism-based (suicide) inhibition — the reaction behind the grapefruit-juice effect He 1998. Furanocoumarins live in the oil; the lipid-lowering polyphenols live in the juice. A product can contain either, both or neither, and the label almost never says. Hold that thought until the safety section, because it is the whole statin interaction.
Cell, rodent, human — and where it stops
In cells. HepG2 and Caco-2 monolayers, bergamot extract and isolated components, cellular cholesterol and HMGCR expression down, brutieridin blocking uptake Huang 2021. Standard flavonoid cell-culture concentrations run in the tens of micromolar.
In rodents. Hyperlipidemic-diet rats given bergamot polyphenolic fraction, with reductions in cholesterol and triglycerides and reported inhibition of HMG-CoA reductase in the animal arm of the same paper that carries the human data Mollace 2011; the wider preclinical metabolic-syndrome literature is collected in Carresi 2020.
In people, and this is the reason bergamot is not filed with the hopefuls. Two hundred and thirty-seven hyperlipidemic patients took bergamot polyphenolic fraction by mouth for 30 days, with total and LDL cholesterol down, HDL up, and triglycerides and blood glucose down Mollace 2011. Seventy-seven hyperlipidemic patients were assigned rosuvastatin 10 or 20 mg, bergamot 1,000 mg, or the combination for 30 days; the combination beat the statin alone on LDL-C and on the oxidative and LOX-1 read-outs Gliozzi 2013. Sixty-four overweight and obese adults with mild hypercholesterolemia took a bergamot phytosome 500 mg twice daily against placebo for 12 weeks, with visceral adipose tissue and total and LDL cholesterol down by 30 days — and, importantly, other metabolic parameters unchanged Rondanelli 2021.
The specific obstacle is that the evidence belongs to a fraction and the shelf sells a genus. Every trial above used a defined preparation: a polyphenolic fraction from the juice Mollace 2011, or a phospholipid-complexed phytosome of it Rondanelli 2021. Neither is “bergamot extract”, and neither is bergamot juice, and neither is bergamot essential oil. The brutieridin and melitidin content is what the mechanism argument rests on Huang 2021, and a bottle that does not quantify total flavanones has not told you whether it contains any.
The second obstacle is trial architecture. The statin-combination study was open-label and parallel-group Gliozzi 2013; the 237-patient study is reported inside a paper that also carries the animal work Mollace 2011. The cleanest design in the set is the 64-person double-blind phytosome trial, and it is the one whose effects were confined to lipids and visceral fat with everything else flat Rondanelli 2021. As trials get tighter the claim gets narrower, which is the ordinary trajectory and should be expected to continue.
Bergamot — which form, and does it matter
Bergamot polyphenolic fraction is a specification. “Citrus bergamot extract” is a plant name. BPF is prepared from the juice and characterized by its flavanone glycoside content, with brutieridin and melitidin as the distinctive markers Huang 2021Carresi 2020. If a label states a total flavanone percentage, or names BPF, you can map it onto the trials. If it says “bergamot fruit extract 500 mg” and nothing else, you cannot, and the honest position is that you do not know what is in it.
Juice fraction versus peel oil is the distinction that matters most and is printed least. Cold-pressed bergamot peel oil is the Earl Gray ingredient and the perfumery ingredient. It is rich in bergapten (5-methoxypsoralen) and bergamottin, and it is where the CYP3A4 and phototoxicity problems live He 1998. The lipid-lowering polyphenols are in the juice, not the oil. A supplement described only as “bergamot” may be either.
Phytosome is a different exposure, not a marketing word. The 12-week trial used a phospholipid complex at 500 mg twice daily Rondanelli 2021, while the statin-combination work used 1,000 mg of the fraction Gliozzi 2013. Flavanone glycosides are poorly absorbed as glycosides — the sugar has to come off, usually by gut bacteria, before the aglycone is taken up. A phospholipid complex changes that step, so milligram-for-milligram comparisons between a phytosome and a plain fraction are not meaningful.
The dose that appears in the trials is 500–1,000 mg/day and the split matters. The double-blind trial split it Rondanelli 2021. Given that the absorption step depends on microbial deglycosylation in the colon, a split dose keeps the colon supplied rather than saturating it once, which is a reasoned extrapolation and is labeled as one.
What would have to be true, and how you would know it was not
1. ApoB down 8–15% by 8–12 weeks at 500 mg twice daily of a characterized fraction. ApoB, not LDL-C, because bergamot's own trial base reports movement in HDL and triglycerides simultaneously Mollace 2011, and when several lipid fractions move at once the particle count is the only number that stays interpretable. Twelve weeks because the LDL pool re-equilibrates in about three weeks and the phytosome trial saw its effect by day 30 Rondanelli 2021.
2. If the LOX-1 arm is real, hs-CRP should move and it should move late. Receptor-level changes at the endothelium show up as inflammation markers, not as lipids. Predict hs-CRP down 0.3–1.0 mg/L at 12 weeks in someone starting above 2 mg/L, and predict it lags the lipid change by weeks Gliozzi 2013. A product that moves LDL and leaves CRP exactly where it was has done the synthesis half and not the vessel-wall half.
3. The prediction that cuts against the product. Lp(a) will not move. It is made and cleared largely independently of the LDL pathway, it is set genetically, and nothing in the bergamot mechanism touches apolipoprotein(a) synthesis. So a reader whose cardiovascular risk is being driven by an Lp(a) of 150 nmol/L should understand that this product cannot address it, and that a satisfying fall in LDL-C on the same report is not the same news. Predict Lp(a) unchanged within assay variation at 12 weeks — and if it does fall by more than 20%, that is a genuinely novel finding worth a doctor's attention rather than a win.
4. Fasting glucose down 3–8 mg/dL, or nothing at all, depending on baseline. The 237-patient report includes glucose Mollace 2011; the tighter 64-person trial found the other metabolic parameters unchanged Rondanelli 2021. Predict the tight trial is closer to the truth in a normoglycemic reader, and that any glucose effect is confined to people who start dysglycemic.
What will fool you: a new muscle ache three weeks in reads as “statin-like effect, must be working”. If you are taking a statin as well, that is the interaction in the safety section and it is worth a creatine kinase, not a shrug.
What nobody has tested yet
Nobody has quantified brutieridin and melitidin in a commercial capsule and then correlated it with response. That is the experiment. The mechanism argument names these two molecules Huang 2021; the trials use fractions whose content is defined in the paper and nowhere on a shelf. Assay ten retail bottles, dose thirty people from each for eight weeks, and plot ApoB change against measured HMG-flavanone content. If the line has a slope, the mechanism is confirmed and label standardization becomes mandatory. If it is flat, the active is something else in the fraction and everybody has been marketing the wrong molecule.
The synthesis-versus-absorption question is unanswered and cheap. Bergamot has a Caco-2 uptake effect and an HMGCR-expression effect in the same paper Huang 2021. Serum lathosterol and desmosterol (synthesis) against campesterol and sitosterol (absorption), before and after 30 days, would say which one dominates in a living person. If it is absorption, bergamot should stack additively with a statin and redundantly with ezetimibe — a clinically useful, entirely untested prediction.
No trial has combined bergamot with a CYP3A4-dependent statin. The one combination trial used rosuvastatin Gliozzi 2013, which is the statin least dependent on CYP3A4 for its clearance. Simvastatin and atorvastatin are the ones a furanocoumarin would actually collide with He 1998, and nobody has run that combination under measurement. The missing experiment is a pharmacokinetic study: simvastatin AUC with and without a defined bergamot product, with the product's furanocoumarin content measured rather than assumed.
And no bergamot trial has ever run long enough to touch an outcome. Thirty days Mollace 2011Gliozzi 2013, twelve weeks Rondanelli 2021. Carotid intima-media thickness over 24 months, or coronary calcium progression, is what a lipid claim eventually has to answer to, and nobody has attempted it.
Bergamot — its own safety story, not its category's
The statin question, answered properly rather than with a warning label. There are two separate interactions and they run in opposite directions. The first is pharmacodynamic and it is the one the trial was designed around: bergamot plus rosuvastatin lowered LDL-C more than rosuvastatin alone Gliozzi 2013, which is the intended, additive, useful version. The second is pharmacokinetic and nobody planned for it: if a bergamot product carries peel-derived furanocoumarins, bergamottin inactivates CYP3A4 He 1998, and simvastatin, lovastatin and to a lesser degree atorvastatin are cleared through CYP3A4. Inhibiting it raises statin exposure, and raised statin exposure is exactly how statin myopathy and rhabdomyolysis happen. Rosuvastatin and pravastatin are largely spared. Read that sequence again: the only published combination trial used the one statin where this interaction is least likely to appear.
What to do about it, concretely. If you take simvastatin, lovastatin or atorvastatin and want to add bergamot, ask the manufacturer in writing whether the product is furanocoumarin-free and at what limit of detection. If the answer is vague, treat the product as grapefruit and behave accordingly. Baseline creatine kinase and a repeat at six weeks costs almost nothing and turns a theoretical interaction into a number.
Phototoxicity, which is a bergamot-specific risk and not a citrus-generic one. Bergapten (5-methoxypsoralen) from the peel is a photosensitizer — it is the reason bergamot oil is restricted in leave-on cosmetics. Oral exposure at supplement doses is a much smaller question than topical, but if a product is oil-derived rather than juice-derived and you are also using a phototherapy lamp, a tanning bed or a photosensitizing drug such as a tetracycline or amiodarone, that is a stack worth avoiding.
Heartburn is the common complaint and it has a cause. This is a concentrated citrus flavanone preparation; reflux and epigastric burning are the usual adverse events, and they are dose- and timing-dependent rather than idiosyncratic. Taking it with food, split twice daily, is the fix.
And the boundary. The trials ran 30 days to 12 weeks in people with mild hypercholesterolemia and metabolic syndrome Mollace 2011Rondanelli 2021. There is no outcome data, no long-term safety data past a few months, and no trial in anyone with established coronary disease. Where a statin is indicated — prior event, familial hypercholesterolemia, a high calcium score — this is an addition, not a substitution, and the trial base itself is built that way.
Sources read for this page
- Mollace V, et al. Hypolipemic and hypoglycaemic activity of bergamot polyphenols: from animal models to human studies.. Fitoterapia 2011 · PMID 21056640
- Gliozzi M, et al. Bergamot polyphenolic fraction enhances rosuvastatin-induced effect on LDL-cholesterol, LOX-1 expression and protein kinase B phosphorylation in patients with hyperlipidemia.. International Journal of Cardiology 2013 · PMID 24239156
- Huang Y, et al. Defining the Cholesterol Lowering Mechanism of Bergamot (Citrus bergamia) Extract in HepG2 and Caco-2 Cells. Nutrients 2021 · PMID 34579033
- Rondanelli M, et al. Bergamot phytosome improved visceral fat and plasma lipid profiles in overweight and obese class I subject with mild hypercholesterolemia: A randomized placebo controlled trial. Phytotherapy Research 2021 · PMID 33188552
- Carresi C, et al. The Effect of Natural Antioxidants in the Development of Metabolic Syndrome: Focus on Bergamot Polyphenolic Fraction. Nutrients 2020 · PMID 32455840
- He K, et al. Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice.. Chemical Research in Toxicology 1998 · PMID 9548795
How you would know if it worked
A citrus polyphenol sold on an HMG-CoA argument is making a lipid claim, and a lipid claim is the most checkable thing in this category. Read ApoB rather than the cholesterol number if you only look at one, because it counts the atherogenic particles instead of the cholesterol riding inside them, which is the honest way to hold a product to a statin-adjacent story. Its own trial base reports lower total and LDL cholesterol and triglycerides with HDL raised, plus movement in glucose and insulin markers, which is why HbA1c is on the list rather than the lipids alone. Run it at 500-1,000 mg of standardized extract, draw at the same lab in the same fasted state, and treat an unchanged ApoB as the answer: this is not doing what it is sold to do in you.
- Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) Retest: Every 3–6 months on androgens; annually otherwise.
- ApoB (Apolipoprotein B) Retest: Every 3–6 months on androgens or after any intervention; annually otherwise.
- HbA1c (Hemoglobin A1c) Retest: Every 3 months (matches red cell lifespan).
The cheapest panel carrying Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) and at least one other of these is The Basics — Start Here, at $36 — the panel is named for a different question, and the marker is the same marker. That is the whole cost of finding out.
Draw before you start, not after. A result with nothing to compare it to answers nothing.
Bergamot — safety & side effects
- Well tolerated; GI upset and heartburn are the usual reports.
- Contains the same statin-like and CYP3A4-inhibiting chemistry as its citrus relatives — caution alongside statins, and muscle pain is a reported effect.
- Additive with lipid-lowering and blood-pressure medication. Not established as safe in pregnancy or breastfeeding — not because harm is documented, but because these are the two populations systematically excluded from the trials. Absence of data is not reassurance.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this against it with a pharmacist or doctor — pharmacists are underused and free.
- When to take it, and what to take it with
- Which form actually absorbs
- Who it's worth it for
- Best-in-class brand pick
- Coach Cam's stacks and notes
- Fasted or with food, and when in the day
- Morning or night, and why that window
- Around training, or deliberately away from it
- What it must not share a window with
Everything above is free and stays free. Skool is where it becomes a plan — Bergamot in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Bergamot
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| ApoB (Apolipoprotein B) | Counts the particles that cause plaque — a normal LDL-C can hide risk |
| Lipoprotein(a) — Lp(a) | Genetic, largely unmodifiable, and worth knowing once in your life |
| hs-CRP (High-Sensitivity C-Reactive Protein) | The inflammatory half of cardiovascular risk |
| Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) | The standard baseline these are usually aimed at |
The Real Cardiovascular Risk panel covers these in one order — 9 markers, $187.60 with the discount applied.
Check results you already have → · All 103 markers A–Z
Bergamot — frequently asked questions
What is Bergamot?
A citrus polyphenol extract with strong evidence for improving cholesterol and metabolic markers — a natural lipid-support option.
What is the suggested dose of Bergamot?
500–1,000 mg standardized extract daily. This is a general reference for education only — statements have not been evaluated by the FDA and this is not medical advice.
Where can I find Bergamot dosing and the full breakdown?
The suggested dose and the full evidence — clinical, correlative and theoretical — are on this page. What's inside Skool is when to take it, which form actually absorbs, the brand worth buying and Coach Cam's stacks.
Where can I buy Bergamot?
Coach Cam sources Bergamot from vetted, top-rated brands on iHerb — use the buy link on this page.
Bergamot inside a finished plan
One arm of 2 Protocol Blueprints, free to read in full.
What Bergamot is used for
Bergamot appears under 1 goal in the goal router.
Related Cardiovascular supplements
Where this goes next
Bergamot is the arm with mortality data of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.